Share on StockTwits

Genocea Biosciences (NASDAQ:GNCA) VP Paul Giannasca sold 6,760 shares of the stock on the open market in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $12.50, for a total transaction of $84,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Genocea Biosciences (NASDAQ:GNCA) traded up 3.72% during mid-day trading on Friday, hitting $12.81. The stock had a trading volume of 8,024 shares. Genocea Biosciences has a 1-year low of $10.90 and a 1-year high of $23.99. The stock has a 50-day moving average of $14.58 and a 200-day moving average of $16.9. The company’s market cap is $222.7 million.

Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Wednesday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.01. On average, analysts predict that Genocea Biosciences will post $-2.10 earnings per share for the current fiscal year.

Genocea Biosciences, Inc is a United States-based clinical-stage company that develops T cell vaccines.

Receive News & Ratings for Genocea Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.